- $1.23m
- -$8.23m
- $0.67m
- 36
- 56
- 36
- 39
Annual balance sheet for Vyant Bio, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
C2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.161 | 3.88 | 2.44 | 20.6 | 10 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.777 | 2.33 | 0.87 | 0.434 | 0.323 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 24.5 | 7.18 | 4.11 | 23.2 | 11.5 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.558 | 0.652 | 0.696 | 1.69 | 2.65 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Long Term Notes Receivable | |||||
Other Long Term Assets | |||||
Total Assets | 35.4 | 14.9 | 8.35 | 37.6 | 15.2 |
Accounts Payable | |||||
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 28.1 | 6.97 | 4.26 | 5.43 | 3.67 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 28.6 | 7.52 | 4.37 | 6.35 | 5.3 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 6.8 | 7.38 | 3.98 | 31.3 | 9.91 |
Total Liabilities & Shareholders' Equity | 35.4 | 14.9 | 8.35 | 37.6 | 15.2 |
Total Common Shares Outstanding |